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Summary
Background: Several clinical studies have shown that poly-
chemotherapy with the taxanes paclitaxel or docetaxel pre-
ceded or followed by cisplatin is associated with important
schedule-dependent differences in toxicities, such as leukocy-
topenia. In general, the pharmacokinetics of both drugs dur-
ing the combined treatment are unaltered, suggesting that a
pharmacodynamic interaction might have occurred.
Materials and methods- In order to gain insight into this
pharmacologic interaction, we performed in vitro drug accu-
mulation studies using peripheral blood leukocytes and a panel
of tumor and non-malignant cell lines with paclitaxel and
docetaxel, as wel as with their respective formulation vehicles
Cremophor EL and Tween 80.
Results: Our results show a significant reduction in the
intracellular cisplatin concentration in leukocytes of up to
42% in the presence of Cremophor EL and Tween 80
as compared to the control. This pharmacodynamic interac-
tion of these surfactants with cisplatin seems to be specific
for haematopoietic cells, and does not occur in solid tumor
cells.
Conclusion: The present data suggest that the pharmaceut-
ical vehicles Cremophor EL and Tween 80 might contribute to
the reduced cisplatin-associated myelotoxicity observed in the
clinical combination chemotherapy studies with paclitaxel and
docetaxel.
Key words: cisplatin, Cremophor EL, drug accumulation,
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Introduction
Paclitaxel (Taxol), an antimicrotubule agent derived
from the stem bark of the Western Yew tree (Taxus
brevifolia), is one of the most promising drugs in the
chemotherapeutic armamentory, with proven antitumor
activity in wide variety of human neoplastic disorders
[1]. Currently, optimization of the usage of paclitaxel is
actively persued, particularly by testing the efficacy of
this drug in combination chemotherapy. One of the
most obvious drug combinations to evaluate is paclitax-
el followed by cisplatin (cis-Pt), since preclinical data
indicated that this combination causes synergistic cyto-
toxicity in a variety of cell lines [2-4], and human tumor
xenograft models [5, 6]. The only partially overlapping
side effects of paclitaxel and cis-Pt, their different mech-
anisms of action, and paclitaxel's activity in cis-Pt-
refractory ovarian cancer also made the combination of
both drugs attractive for further clinical exploration [7].
Recently, exciting results have emerged from clinical
combination chemotherapy studies with paclitaxel or its
semisynthetic analogue docetaxel (Taxotere) and cis-Pt,
testing two sequences of drug administration [8, 9].
These studies revealed important schedule-dependent
differences in frequency and severity of toxicities, with
less severe myelotoxicity when the taxane was given
before cis-Pt. Our own previous investigations demon-
strated that in the sequence of docetaxel followed by cis-
Pt, the reduced leukocytopenia was accompanied by a
significant inhibition of cis-Pt uptake and DNA-adduct
formation in peripheral blood leukocytes as compared
to the alternate sequence [10,11].
At present, convincing data on the fundamental
mechanisms behind this clinically important pharmaco-
logic interaction are lacking. This prompted us to fur-
ther investigate the effects of paclitaxel and docetaxel, as
well as of their respective formulation vehicles Cremo-
phor EL and Tween 80, on the intracellular accumula-
tion of cis-Pt in haematopoietic and tumor cells in vitro.
Our results show that not the taxanes themselves, but
the polyoxyethylated surfactants Cremophor EL and
Tween 80 selectively inhibit cis-Pt uptake in peripheral
blood leukocytes and bone marrow cells, and suggest
that these vehicles are major determinants in the re-
duced c/s-Pt-associated myelotoxocity observed in clin-
ical combination chemotherapy studies with paclitaxel
and docetaxel.
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Materials and methods
Drugs and chemicals
The cis-Pt reference material was supplied by Pharmachemie (Haarlem,
the Netherlands) as a solution containing 1 mg/ml of drug in D5NS
(lot 95F29MQ. Paclitaxel powder, the clinical paclitaxel formulation
in Cremophor EL and dehydrated ethanol USP (1:1, v/v; Taxol) and
carboplatin were obtained from Bristol-Myers Squibb (Princeton, NJ,
USA). Docetaxel and the clinical docetaxel formulation in Tween 80
(Taxotere) originated from Rhone-Poulenc Rorer (Antony Cedex,
France). Camptothecin lactone (Pharmacia Inc., New Mexico), doxo-
rubicin (Farmitalia Carlo Erba, Milan, Italy), methotrexate (Pharma-
chemie) and vincristine (Eli Lilly, Nieuwegein, the Netherlands) were
used as their pharmaceutical formulations for clinical use without
further purification. Cremophor EL (polyoxyethyleneglycerol tririci-
noleate 35; lot 32H0925), Tween 80 (polyoxyethyleneglycerol sorbitan
monooleate; lot 95H09251), castor oil and ricinoleic acid were pur-
chased from Sigma Chemical Co. (St. Louis, MO, USA). Five reversed-
phase HPLC fractions of Cremophor EL were kindly donated by
Dr David Kessel (Wayne State University School of Medicine, Detroit,
USA) [12]. Formic acid, tetrahydrofuran, ammonium hydroxide and
Triton X-100 were from Baker (Deventer, the Netherlands). Coomassie
Brilliant Blue G-250 was purchased from Bio-Rad Laboratories (Mun-
chen, Germany). All other chemicals and reagents were of analytical or
HPLC grade and were obtained from Rathburn (Walkerburn, UK).
Water was filtered and deionized with a Milli-Q-UF Plus system
(Millipore, Bedford, MA, USA), and was used in all aqueous solu-
tions.
Cell cultures
The human ovarian carcinoma cell lines A2780 and IGROV-1, the
breast carcinoma cell line MCF-7, the human promyelocytic leukae-
mia cell line HL-60 and the murine lymphoid leukaemia cell line P388
were grown and maintained in RPMI1640 medium (Brunschwig,
Amsterdam, the Netherlands). The non-malignant Chinese hamster
ovary (CHO) and the African green monkey kidney (VERO) cell lines
were maintained in Dulbecco's modified Eagle's Medium (DMEM;
Brunschwig). The cells were cultured in a humidified atmosphere in 5%
CO2 at 37 °C in media supplemented with 10% (w/v) of heat-inactivated
bovine calf serum (Hyclone, Logan, UT, USA), 100 U/ml of penicil-
line, 100 ug/ml of streptomycin and 2 mM freshly added L-glutamine
(all from Life Technologies, Gaithersburg, MD, USA). The cytotoxicity
of Cremophor EL against the cells was estimated with the sulforhod-
amine B assay [13].
For peripheral blood leukocytes (PBL) isolation, 55 ml of a freshly
prepared buffy coat suspension obtained from healthy volunteers was
mixed with 50 ml of 0.1 M phosphate buffer and 300 ml of red cell
lysing buffer (composed of 0.83% (w/v) of ammonium chloride and
0.1% (w/v) of potassium carbonate in 1 mM of EDTA). Prior to drug
exposure, the mixture was incubated for 20 min at 4 °C in a water bath.
After centrifugation, the PBL were washed with PBS (Unipath Ltd.,
Basingstoke, UK) and maintained in RPMII640 medium for 45 min.
Isolation of gTanulocytes and mononuclear cells from heparinized
human blood was performed by sequential ficoll-gradient centrifuga-
tion and methyl cellulose sedimentation at room temperature as
described [14]. Contaminating erythrocytes were removed by hypotonic
lysis in 0.22% (w/v) of sodium chloride for five minutes. Both post-
ficoll cell fractions were handled further as described above for whole
PBL.
Bone marrow samples were collected from female Wistar rats
obtained from the Erasmus Animal Experimental Centre (Rotterdam,
the Netherlands), that were housed in conventional plastic cages
covered with filter bonnets, and provided with food and water ad
libitum. The animals were sacrified by cervical dislocation under
diethylether anaesthesia, and femurs were removed surgically, scraped
free of muscular tissues and other adhering debris, while maintaining
the integrity of the knee and hip joints during dissection. The marrow
was harvested by snipping the tip of the femur and flushing with ice-
cold PBS using a syringe fitted with a 27-gauge needle. Cell suspen-
sions were stored on ice and used within one hour of collection.
Cellular drug accumulation
All cell lines were grown to 60%-70% confluence in 75 cm2 cell culture
flasks (Greiner, Alphen a/d Rijn, the Netherlands), and incubated
simultaneously for two hours with Cremophor EL and cis-Px (10 ug/
ml). Immediately after drug incubation, the cells were rinsed twice with
PBS, harvested by trypsinization, and washed three times with PBS.
For the accumulation studies in PBL and bone marrow cells, 6 ml
of the cell suspension were incubated in 12.5 ml polypropylene screw-
cap tubes (Greiner) with various concentrations of the drugs or surfac-
tants and cis-Px for two hours. During this incubation, the tubes were
vortex-mixed at 30 min-intervals to prevent clogging of the cells. Next,
samples were processed as described above for tumor cells.
Drag analyses
Cell pellets were digested with 500 ul of Triton X-100-water (1:500, v/v)
by vortex-mixing (five minutes) and ultrasonication (15 minutes). A
100 ul-aliquot of this solution was removed for determination of the
protein content by the method of Bradford [15]. The remaining cell
lysate was then analyzed for total platmum by flameless atomic
absorption spectrometry using a Perkin Elmer Model 4110 ZL atomic
absorption spectrometer with Zeeman-background correction (Perkin
Elmer Corp., Rockville, MD, USA) as described previously [16]. Each
sample was analysed in duplicate by external standardization with a
weighted linear regression analysis (1/x2), and the absorbance readings
were averaged.
For the analysis of intracellular paclitaxel and docetaxel concen-
trations, PBL pellets were digested in 1000 ul of water, followed by
liquid-liquid extraction and reversed-phase HPLC according to meth-
ods reported in detail previously [17, 18]. The HPLC equipment was
composed of a constaMetric 3200 pump (LCD Analytical, Rivera
Beach, CA, USA), a Waters Model 717 plus autosampler (Milford,
MA, USA) and a UV-2000 detector (Spectra Physics, San Jose, CA,
USA). Separations were achieved on an Inertsil ODS-80A column
(GL Science, Tokyo, Japan) and a mobile phase of methanol-tetra-
hydrofuran-20% (w/v) ammonium hydroxide (60:2.5:37.5, v/v/v; pH
6.0), delivered at 1.00 ml/min. Detection was performed at 230 nm,
with peak recording performed using the Chrom-Card data analysis
system (Fisons, Milan, Italy). Calibration curves were fitted by
weighted regression analysis (1/x2).
Cremophor EL concentrations in plasma collected from two pa-
tients receiving 100 and 225 mg/m2 of paclitaxel (three-hour i.v.
infusion), respectively, followed by 70 mg/m2 of cis-Pt (three-hour i.v.
infusion) were measured by a novel microassay that will be described
in detail elsewhere [19]. In brief, the method is based on a selective
binding of Coomassie Brilliant Blue G-250 to Cremophor EL follow-
ing plasma protein precipitation with acetonitrile and liquid-liquid
extraction with n-butylchloride. The increase in the absorption max-
imum of the dye from 465 to 595 nm after binding to Cremophor EL
was monitored using a Titertec automated microplate reader (Flow
Laboratories, Irvine, UK). Calibration curves constructed in blank
human plasma over the concentration range of 0.05%-1.0% (v/v) of
Cremophor EL were fitted by using unweighted second-order polyno-
mial (quadratic) regression analysis.
Results
In order to gain insight into the pharmacologic mecha-
nism of interaction involved in our clinical studies with
paclitaxel or docetaxel and cis-Pt, in vitro drug accumu-
lation studies were performed using both PBL, isolated
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Table 1. Cellular accumulation of cis-Pt in PBL following a two-hour
simultaneous in vitro incubation of various drugs and pharmaceutical
formulation vehicles and cis-Pt (10 ug/ml). Data are presented as a
mean percentage relative to a 100% control value ± SD.
Table 2. Cellular accumulation of paclitaxel, docetaxel and carbopla-
tin in PBL following a two-hour simultaneous in vitro incubation with
Cremophor EL or Tween 80 (0.01%). Data are presented as a mean
percentage relative to a 100% control value ± SD.
Drug (formulation) Concentration C/5-Pt
accumulation (%)
Paclitaxel (Cremophor EL)
Paclitaxel (DMSO)
Docetaxel (Tween 80)
Docetaxel (DMSO)
Cremophor EL
Tween 80
Ethanol
Camptothecin
Doxombicin
Methotrexate
Vmcnstine
1.0 ug/ml
1.0 ug/ml
1.0 ug/ml
1.0 ug/ml
1.0%
0.01%
0.001%
0.0001%
0.00001%
0.01%
0.01%
1.0 ug/ml
1.0 ug/ml
1.0 ug/ml
1.0 ug/ml
67 ± 12*
99 ±8
73 ± 13'
101 ± 13
52 ±9*
58 + 10"
62 ± 11"
66± 11'
75 ±2*
58 ±8*
94 ±7
105 ±9
101 +3
104 ±9
94 ± 16
3
2
3
3
2
11
5
2
2
3
3
3
3
3
3
' f < 0.05 versus the control value.
from freshly prepared buffy coat suspensions, and vari-
ous tumor and normal cell lines. The total cellular accu-
mulation of the drugs used in these experiments was
quantitated as a percentage relative to the 100% control
value, which was assigned to the drug level achieved
without co-incubation at the specified treatment interval.
Simultaneous incubation of PBL with Taxol (i.e.,
paclitaxel formulated in Cremophor EL) or Taxotere
(i.e., docetaxel formulated in Tween 80) and cis-Pt re-
sulted in a similar magnitude of cis-Pt uptake inhibition,
with the intracellular concentrations of cis-Pt in PBL
being significantly reduced by 33% and 27% for Taxol
and Taxotere, respectively, as compared to the control
values (Table 1).
Because the possibility existed that the reduced cis-Pt
accumulation in PBL after co-incubation with Taxol or
Taxotere was due to the large amounts of Cremophor
EL and Tween 80 added to the cells, PBL were also
treated with Cremophor EL or Tween 80 alone prior to
cis-Pt (Table 1). In these experiments, a significant re-
duction in the intracellular cz's-Pt concentration in PBL
of 42% compared to the control was observed in the
presence of 0.01% (v/v) of Cremophor EL or Tween 80
(i.e., the same concentrations present in 1.0 ug/ml of
Taxol and Taxotere, respectively). Further studies re-
vealed a clear concentration-dependent effect of Cremo-
phor EL on the cis-Pt uptake in PBL, with maximal
inhibition (approximately 50%) achieved at an extracel-
lular concentration of 1.0% of Cremophor EL. It is of
interest to note, however, that Cremophor EL concen-
trations as low as 0.00001% still resulted in a mere 25%
decrease in cis-Pt uptake as compared to the control
(Table 1). The increased cis-Pt levels observed in PBL
incubated in higher concentrations of Cremophor EL
(^10%) was not due primarily to interference with
uptake, but rather to gross cellular damage (data not
Drug
(formulation)
Paclitaxel
(DMSO)
Docetaxel
(DMSO)
Carboplatin
(water)
Concentra-
tion
1.0 ug/ml
1.0 ug/ml
100 ug/ml
Drug
accumulation
with Cremo-
phor EL
94 ± 11
94 ±6
112± 13
n
6
3
4
Drug
accumulation
with Tween 80
105 ± 14
96 ±7
95 ±4
71
4
3
3
shown). The cis-Pt accumulation was unaffected in a
similar set of experiments in which cells were exposed to
paclitaxel or docetaxel formulated without Cremophor
EL or Tween 80 (viz. DMSO) (Table 1). These findings
indicate that the inhibition of cis-Pt accumulation in
PBL observed with Taxol and Taxotere is exclusively
caused by their formulation vehicles Cremophor EL
and Tween 80.
Incubation of PBL with pure castor oil and ricinoleic
acid, two major components present in the Cremophor
EL vehicle prior to polyoxyethylation, showed no evi-
dence of any decrease in cis-Pt accumulation (data not
shown). Furthermore, experiments with five reversed-
phase HPLC fractions of Cremophor EL (each with
progressively increased hydrophobicity) indicated that
the inhibitory effects of the unfractionated vehicle on
cis-Pt uptake is not observed with the more hydrophilic
components present in fraction I, mainly containing
polyethylene glycol and oxyethylated glycerol (data not
shown). The maximum concentration of ethanol, anoth-
er component of the paclitaxel formulation, to which the
cells were exposed was 0.01% (v/v). Although it was
unlikely that such low concentrations would contribute
to the observed effects, it was necessary to rule out this
organic solvent as an important contributor to the de-
creased cis-Pt accumulation. To date, in the cases where
cells were exposed to ethanol in the absence of drug, the
cellular accumulation of cis-Pt was identical to the con-
trol (Table 1). In addition, a number of other drugs,
formulated without a polyoxyethylated surfactant, in-
cluding camptothecin, doxorubicin, methotrexate and
vincristine had no effect on the accumulation of cis-Pt
at the specified concentrations (Table 1).
PBL were also treated with paclitaxel, docetaxel
(both formulated in DMSO) or the cis-Pt analogue
carboplatin and the surfactants, to determine whether
the observed mechanism of interaction was specific for
cis-Pt. At drug concentrations chosen close to achiev-
able plasma levels in vivo, both Cremophor EL and
Tween 80 had negligible effects on drug accumulation
(Table 2).
To test whether the pattern of cis-Pt uptake in the
presence of Cremophor EL (at non-cytotoxic concen-
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Table 3. Cellular accumulation of cis-Pt in various cell lines following
a two-hour simultaneous m vitro incubation of Cremophor EL (0.01%)
and cis-Pl (10 ug/ml). Data are presented as a mean relative to a 100%
control value ± SD.
0.60
Cell line
Malignant
A2780
IGROV-1
MCF-7
HL-60
P388
Non-malignant
CHO
VERO
Granulocytes
Mononuclcar
cells
Bone marrow
Origin
Human ovarian
carcinoma
Human ovarian
carcinoma
Human breast
carcinoma
Human
promyelocytic
leukaemia
Munne lymphoid
leukaemia
Chinese hamster
ovary
African green
monkey kidney
Human blood
Human blood
Wistar rat
cis-Pl
accumulation
98 ± 8
96 ± 10
102 ± 9
77 ± 12"
84±5 b
93 ± 4
111 ± 11
82 ± lb
7 6 ± 3 b
84 ± lb
n
3
3
2
5
4
3
3
4
4
2
Cremophor EL
ICMC/4)*
0.047 ±0.009
ND
0.068 ±0 008
ND
ND
0.092 ±0.010
0.093 ±0.015
ND
ND
ND
n
2
.-
2
-
-
2
2
_
-
-
* Dose of Cremophor EL to produce a 50% inhibition of normal cell
growth during a five-day continuous exposition.
b
 P < 0.05 versus the control value.
trations; Table 3) was also altered in other mammalian
cells, cis-Pt influx was examined in the tumor cell lines
A2780, IGROV-1, MCF-7, HL-60 and P388, the non-
malignant cell lines CHO and VERO, and rat bone
marrow cells identically to incubations performed in
PBL. As depicted in Table 3, a significant decrease in
the intracellular cis-Pt concentration was only observed
in the leukaemic cell lines and the rat bone marrow cells.
Furthermore, the effect of Cremophor EL on the cis-Pt
uptake in PBL was not lineage specific, as indicated by
the results from incubation experiments using isolated
granulocytes and mononuclear cells (Table 3). In all,
these data indicate a selective protection of haemato-
poietic cells by Cremophor EL against cis-Pt uptake
at concentrations that can be maintained in humans
for several hours after i.v. paclitaxel administration
(Figure 1).
Discussion
Cis-Pt is one of the most active anticancer agents. The
drug is part of curative treatment in some diseases,
however, most patients will eventually relapse after con-
ventional three-weekly cis-Pt treatment as a result of
cellular resistance to the drug. Our current hypothesis is
that dose-intensification by shortening dose-intervals
might be an approach to overcome clinical drug resist-
ance. We have recently tested this concept in non-small
cell lung cancer and ovarian cancer by giving cis-Pt
weekly instead of three-weekly and demonstrated in-
creased response rates of up to 52% and 90%, respec-
0.00 4
10 20 30
time (h)
Figure 1. Plasma concentration versus time profile of Cremophor EL
in two female patients with advanced ovarian cancer, treated with a
three-hour intravenous infusion of paclitaxel at dose levels of 100 mg/
m2 and 225 mg/m2. Paclitaxel was formulated at 6 mg/ml in a mixture
of Cremophor EL-dehydrated ethanol USP (1:1, v/v), and diluted 20-
fold in normal saline to a final concentration of 0.3 mg/ml within three
hours before drug administration. Patients one (circles) and two
(triangles) received absolute Cremophor EL doses of 13.8 and 27.9 ml,
respectively.
tively [20, 21]. In these studies, however, cw-Pt-induced
leukocytopenia appeared to be the dose-limiting toxicity.
In contrast, weekly combination chemotherapy with cis-
Pt and paclitaxel resulted in significantly less haemato-
logical toxicities than anticipated (unpublished data).
The present study demonstrates that this effect may be
related to a selective inhibition of cis-Pt accumulation in
PBL and bone marrow cells by the paclitaxel vehicle
Cremophor EL, which is not lineage specific. These data
are in agreement with our pevious findings of reduced ex
vivo cis-Pt induced DNA-adduct levels in PBL obtained
from patients three hours after treatment with paclitaxel
compared to PBL from non-pretreated patients [16].
The different effects of Cremophor EL on the in vitro
cis-Pt uptake in normal haematopoietic cells and (solid)
tumor cells, respectively, suggest that administration of
Cremophor EL could selectively provide protection
against cis-Pt uptake in haematopoietic cells, without
affecting antitumor activity. Support for this hypothesis
can be derived from several clinical and pharmacoki-
netic phase I studies in patients with solid tumors,
applying the sequence paclitaxel or docetaxel followed
by cis-Pt in one group of patients and that of cis-Pt
followed by paclitaxel or docetaxel in another group [8,
9]. These combination chemotherapy studies revealed
clinically important schedule-dependent differences in
frequency and severity of toxicities, whereas antitumor
activity did not seem to be affected.
The extracellular levels of Cremophor EL used in our
in vitro experiments were shown to be maintained in
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patients for several hours after i.v. administration of
paclitaxel, even at dose levels as low as 100 mg/m2. These
results are consistent with previously published measure-
ments of Cremophor EL concentrations in plasma by
pre-column derivatization and reversed-phase HPLC
[22, 23]. Previous studies also demonstrated that the
distribution volume of Cremophor EL in mice (0.14 I/kg)
was less than the volume of the plasma and the extrac-
ellular compartment (approximately 0.2 I/kg), indicat-
ing that the tissue distribution of Cremophor EL is
insignificant [24]. These data imply that even very low
doses of Cremophor EL would still result in an extended
exposure of bone marrow cells to levels of Cremophor
EL providing protection against cellular cis-Pt uptake.
Recent studies in mice showed that such low i.v. doses of
Cremophor EL did not result in localized toxicity or
marrow destruction [25], which is consistent with flow
cytometric studies demonstrating that even very high
concentrations of Cremophor EL (> 10%) did not lyse
bone marrow cell membranes [26]. Moreover, the i.v.
administration of Cremophor EL was associated with
an increase in the incidence of both primitive and
committed progenitors, and protected mice from irra-
diation-induced death [25]. These findings provide a
rationale for attempts to circumvent cw-Pt-associated
myelotoxicity by concomitant administration of Cremo-
phor EL.
Cremophor EL is a complex heterogeneous liquid
formed by the reaction of ethylene oxide with castor oil
at a molar ratio of 35 :1 [27]. Separation of Cremophor
EL into a series of components based on reversed-phase
HPLC provided additional information on the nature of
the pharmacologically active constituents. These studies
show that maximal inhibition of cis-Pt uptake in PBL
was achieved with the more hydrophobic components of
the mixture, mainly containing polyoxyethyleneglycerol
triricinoleate along with fatty acids esters of polyethyle-
neglycol. AsTween 80 is a polyoxyethylated derivative of
sorbitan monooleate, the active agents apparently con-
tain hydrophilic polyoxyethylated side chains attached
to hydrophobic moieties with no structural similarities.
The biochemical mechanism of the dose-dependent
interaction of Cremophor EL with the cellular uptake of
cis-Pt is not clear. It has been reported that Cremophor
EL can have a major (reversible) effect on the micro-
viscosity of cell membranes, thereby interfering with
passive drug diffusion [26]. However, recent experiments
demonstrated that cis-Pt accumulation in PBL was
highly temperature dependent. Lowering the tempera-
ture from 37 to 4 °C led to 70% and 90% reduction of
intracellular cis-Pt in the absence or presence of Cremo-
phor EL, respectively (unpublished data). This would
imply that besides passive diffusion, alternative trans-
port systems for cis-Pt susceptable to modulation by
Cremophor EL are present in PBL. Such mechanisms
include facilitated diffusion through gated tunnels regu-
lated by phosphorylation cascades initiated by activa-
tion of protein kinase C [28, 29]. These and several other
possibilities are currently under investigation.
The lack of interaction between Cremophor EL and
the cis-Pt analogue carboplatin in our in vitro model
in PBL is in line with previous clinical observations
demonstrating a sequence-independent effect on the
myelotoxicity of the combination paclitaxel and carbo-
platin [30, 31]. In point of fact, in contrast to studies
combining paclitaxel or docetaxel and cis-Pt, no dimin-
uition in expected leukocytopenia has been reported in
any of the trials with paclitaxel /carboplatin combina-
tion chemotherapy [32]. Several recent studies, however,
found that this combination was better tolerated than
anticipated, particularly with respect to thrombocyto-
penia [33]. The mechanism underlying this observation
remains to be elucidated.
In conclusion, this study provides evidence supportive
of the conjecture that the pharmaceutical vehicles Cre-
mophor EL and Tween 80 are major determinants in the
reduced m-Pt-associated myelotoxocity observed in
clinical combination chemotherapy studies with pacli-
taxel and docetaxel. Furthermore, the pharmacokinetic
selectivity for the central blood/bone marrow compart-
ment, combined with a direct protection of normal
haematopoietic cells by limitation of m-Pt uptake make
Cremophor EL a promising candidate for the selective
modulation of m-Pt-induced myelotoxicity in a clinical
setting of short-interval cis-Pt administration. Presently,
this concept is under investigation in a rodent tumor-
bearing model.
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